By vgreene, 22 June, 2015 Monitor ALT/AST, HBsAg, HBeAg, HBV DNA levels, renal function<sup>29</sup> and adherence annually [S/M]; exceptions:
By vgreene, 22 June, 2015 Treat w/ nucleos(t)ide analogues<sup>22,23</sup> w/high drug resistance barrier<sup>24</sup> [S/M]; options:
By vgreene, 22 June, 2015 Entecavir:<sup>28</sup> 0.5 mg PO daily if compensated liver dz and lamivudine naïve; 1 mg PO daily if decompensated liver dz [S/M]
By vgreene, 22 June, 2015 Monitor ALT/AST, HBsAg, HBeAg, HBV DNA levels, and assess for cirrhosis q6-12mo [S/M]:
